Lite Strategy, Inc.

Lite Strategy (formerly known as MEI Pharma Inc) adopts a Litecoin treasury strategy. The rebranding reflects the company’s strategic pivot to using Litecoin as its primary reserve asset while maintaining its pharmaceutical activities. Lite Strategy indicated it continues to evaluate its drug candidate pipeline, including plans to identify new development opportunities for voruciclib and zandelisib. GSR is providing liquidity, risk management, and strategic insight to support Lite Strategy’s adoption of Litecoin as a core treasury asset. The company stated its rebranding aligns with its mission to expand access to compliant digital asset exposure while seeking to enhance shareholder value.